Hi Ahmed, are you referring to the pipeline mentioned by the company, below?
Positive results for DMX-200 would go some way to proving that Dimerix's Receptor HIT drug discovery platform is effective and likely to be effective again in these areas. I agree it would be good to out-licence DMX-200 and then work on the program below. It's a solid pipeline.
Ann: Shareholder Briefing, page-85
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $231.2M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 41.8¢ | $1.239M | 2.905M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 257588 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |